[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE381345T1 - Alpha-emittierende konstrukte sowie deren verwendung - Google Patents

Alpha-emittierende konstrukte sowie deren verwendung

Info

Publication number
ATE381345T1
ATE381345T1 AT99940789T AT99940789T ATE381345T1 AT E381345 T1 ATE381345 T1 AT E381345T1 AT 99940789 T AT99940789 T AT 99940789T AT 99940789 T AT99940789 T AT 99940789T AT E381345 T1 ATE381345 T1 AT E381345T1
Authority
AT
Austria
Prior art keywords
cells
alpha
constructs
emitting
emitting constructs
Prior art date
Application number
AT99940789T
Other languages
English (en)
Inventor
David Scheinberg
Dangshe Ma
Michael Mcdevitt
George Sgouros
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE381345T1 publication Critical patent/ATE381345T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Revetment (AREA)
AT99940789T 1998-05-26 1999-05-26 Alpha-emittierende konstrukte sowie deren verwendung ATE381345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8677298P 1998-05-26 1998-05-26

Publications (1)

Publication Number Publication Date
ATE381345T1 true ATE381345T1 (de) 2008-01-15

Family

ID=22200805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940789T ATE381345T1 (de) 1998-05-26 1999-05-26 Alpha-emittierende konstrukte sowie deren verwendung

Country Status (7)

Country Link
EP (1) EP1091757B1 (de)
JP (1) JP5064608B2 (de)
AT (1) ATE381345T1 (de)
CA (1) CA2333125C (de)
DE (1) DE69937797D1 (de)
ES (1) ES2299256T3 (de)
WO (1) WO1999061097A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
EP2326350B1 (de) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Verbindungen zur tötung von psma-expriemierenden und taxane-resistenten krebszellen
CN102596258B (zh) * 2009-07-22 2015-01-28 锕医药股份有限公司 用于制备放射性免疫缀合物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282057A3 (de) * 1987-03-11 1990-03-07 The Board Of Regents Of The University Of Michigan Chemo-Radio-Immunkonjugate
WO1991009058A1 (en) * 1989-12-14 1991-06-27 Sloan-Kettering Institute For Cancer Research Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
JP5064608B2 (ja) 2012-10-31
EP1091757B1 (de) 2007-12-19
EP1091757A2 (de) 2001-04-18
EP1091757A4 (de) 2002-08-07
WO1999061097A3 (en) 2000-02-03
WO1999061097A9 (en) 2000-06-02
CA2333125C (en) 2009-12-15
CA2333125A1 (en) 1999-12-02
ES2299256T3 (es) 2008-05-16
DE69937797D1 (de) 2008-01-31
JP2002516297A (ja) 2002-06-04
WO1999061097A2 (en) 1999-12-02

Similar Documents

Publication Publication Date Title
ATE417604T1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
MY121548A (en) Compounds and methods for the treatment of cancer
FI951295A (fi) Ihon läpi tapahtuva veressä olevien valoherkkien aineiden in vivo-aktivointi
GB8919251D0 (en) Compounds
ATE500808T1 (de) Onkolytische virustherapie
ATE263252T1 (de) Erzielbare vektorenpartikel
ATE33556T1 (de) Adenosinderivate enthaltende pharmazeutische zusammensetzung fuer behandlung von tumoren.
ES2133412T3 (es) 2',5'-oligoadenilato-2',3'-ciclofosfatos y 2',5'-oligoadenilatos con actividad sobre el virus papiloma.
AR007493A1 (es) Microparticulas secadas por rociado como vehiculos terapeuticos para uso en terapia genetica
ATE260692T1 (de) Drahtförmige strahlungsquelle zur endovaskulären bestrahlung
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
ATE381345T1 (de) Alpha-emittierende konstrukte sowie deren verwendung
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
HU9201197D0 (en) Protection from shock subsequent to injury by double-stranded rns
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
Beer et al. Reassessment of the differential effects of ultraviolet and ionizing radiation on HIV promoter: the use of cell survival as the basis for comparisons
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE407702T1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
ATE353639T1 (de) In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb
DE3883044D1 (de) Wirkstoff zur tumorbekaempfung.
Strander The action of interferons on virus-associated human neoplasms
DE69803052D1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
Fonseca et al. Photodynamic therapy effect on the ultrastructure of Trichomonas vaginalis trophozoites and their effectiveness in experimentally infected animals
Rajarami Reddy et al. Effects of x-irradiation on some aspects of protein metabolism in the frog, Rana hexadactyla

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties